Philipp Müller

2.5k total citations
33 papers, 1.9k citations indexed

About

Philipp Müller is a scholar working on Oncology, Immunology and Surgery. According to data from OpenAlex, Philipp Müller has authored 33 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Immunology and 9 papers in Surgery. Recurrent topics in Philipp Müller's work include Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (9 papers) and CAR-T cell therapy research (8 papers). Philipp Müller is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (9 papers) and CAR-T cell therapy research (8 papers). Philipp Müller collaborates with scholars based in Switzerland, Germany and Austria. Philipp Müller's co-authors include Alfred Zippelius, Jens Schreiner, Patrick R. Schmidlin, Bernhard Guggenheim, Petra Herzig, Daniela S. Thommen, Didier Lardinois, Kea Martin, Martin F. Bachmann and Patrik Maurer and has published in prestigious journals such as The Lancet, Nature Communications and PLoS ONE.

In The Last Decade

Philipp Müller

31 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philipp Müller Switzerland	18	981	706	374	371	230	33	1.9k
Bruce L. Daugherty United States	21	608 0.6×	1.1k 1.5×	191 0.5×	565 1.5×	264 1.1×	50	2.3k
Lauren J. Lahey United States	28	189 0.2×	723 1.0×	465 1.2×	631 1.7×	171 0.7×	37	2.5k
D Henriksen-DeStefano United States	10	355 0.4×	959 1.4×	176 0.5×	519 1.4×	166 0.7×	10	1.9k
Pier Adelchi Ruffini Italy	21	837 0.9×	1.5k 2.2×	161 0.4×	646 1.7×	104 0.5×	47	2.4k
Roger Palframan United Kingdom	18	474 0.5×	1.3k 1.9×	165 0.4×	378 1.0×	276 1.2×	22	2.3k
Cristina Maria Failla Italy	27	638 0.7×	462 0.7×	428 1.1×	1.2k 3.2×	87 0.4×	58	2.9k
Nicole A. Mifsud Australia	25	321 0.3×	1.1k 1.6×	244 0.7×	585 1.6×	92 0.4×	78	2.1k
Iwao Sekigawa Japan	29	323 0.3×	1.1k 1.6×	245 0.7×	509 1.4×	66 0.3×	112	2.2k
Kinji Shirota Japan	16	399 0.4×	280 0.4×	354 0.9×	581 1.6×	239 1.0×	112	1.8k
Arabella B. Tilden United States	25	543 0.6×	1.3k 1.8×	353 0.9×	348 0.9×	55 0.2×	51	2.1k

Countries citing papers authored by Philipp Müller

Since Specialization

Citations

This map shows the geographic impact of Philipp Müller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philipp Müller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philipp Müller more than expected).

Fields of papers citing papers by Philipp Müller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philipp Müller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philipp Müller. The network helps show where Philipp Müller may publish in the future.

Co-authorship network of co-authors of Philipp Müller

This figure shows the co-authorship network connecting the top 25 collaborators of Philipp Müller. A scholar is included among the top collaborators of Philipp Müller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philipp Müller. Philipp Müller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Holzgreve, Adrien, Julian Taugner, Lukas Käsmann, et al.. (2023). Metabolic patterns on [18F]FDG PET/CT in patients with unresectable stage III NSCLC undergoing chemoradiotherapy ± durvalumab maintenance treatment. European Journal of Nuclear Medicine and Molecular Imaging. 50(8). 2466–2476. 9 indexed citations

Reschke, Markus, Frederik H. Igney, Peter Maier, et al.. (2022). Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96. Biomedicines. 10(9). 2146–2146. 2 indexed citations

D’Amico, Lucia, Ulrike Menzel, Michael Prummer, et al.. (2019). A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. Journal for ImmunoTherapy of Cancer. 7(1). 16–16. 89 indexed citations

Kimpel, Janine, Fabian Heinemann, Birgit Stierstorfer, et al.. (2019). The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer. British Journal of Cancer. 121(8). 647–658. 32 indexed citations

Läubli, Heinz, Philipp Müller, Lucia D’Amico, et al.. (2018). The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models. Cancer Immunology Immunotherapy. 67(5). 815–824. 42 indexed citations

Kallert, Sandra M., Stéphanie Darbre, Weldy V. Bonilla, et al.. (2017). Replicating viral vector platform exploits alarmin signals for potent CD8+ T cell-mediated tumour immunotherapy. Nature Communications. 8(1). 15327–15327. 64 indexed citations

Müller, Philipp, Daniela S. Thommen, & Alfred Zippelius. (2016). Agonistic anti-CD40 therapy synergizes with LAG-3-blocking antibodies. International Journal of Clinical Pharmacology and Therapeutics. 55(8). 692–694. 1 indexed citations

Müller, Philipp, Matthias Kreuzaler, Tarik A. Khan, et al.. (2015). Trastuzumab emtansine (T-DM1) renders HER2 ⁺ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Science Translational Medicine. 7(315). 315ra188–315ra188. 269 indexed citations

Zippelius, Alfred, Jens Schreiner, Petra Herzig, & Philipp Müller. (2015). Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment. Cancer Immunology Research. 3(3). 236–244. 112 indexed citations

10.

Thommen, Daniela S., Jens Schreiner, Philipp Müller, et al.. (2015). Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. Cancer Immunology Research. 3(12). 1344–1355. 315 indexed citations

11.

Müller, Philipp, et al.. (2015). Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. Cancer Immunology Immunotherapy. 65(1). 1–11. 35 indexed citations

12.

Schreiner, Jens, Daniela S. Thommen, Petra Herzig, et al.. (2015). Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. OncoImmunology. 5(2). e1062969–e1062969. 28 indexed citations

13.

Müller, Philipp, Kea Martin, Sebastian Theurich, et al.. (2014). Microtubule-Depolymerizing Agents Used in Antibody–Drug Conjugates Induce Antitumor Immunity by Stimulation of Dendritic Cells. Cancer Immunology Research. 2(8). 741–755. 150 indexed citations

14.

Martin, Kea, Philipp Müller, Jens Schreiner, et al.. (2014). The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. Cancer Immunology Immunotherapy. 63(9). 925–938. 60 indexed citations

15.

Müller, Philipp, Bernhard Guggenheim, Thomas Attin, Ernst Marlinghaus, & Patrick R. Schmidlin. (2010). Potential of shock waves to remove calculus and biofilm. Clinical Oral Investigations. 15(6). 959–965. 26 indexed citations

16.

Cornuz, Jacques, W. F. Jungi, Joseph Österwalder, et al.. (2008). A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial. PLoS ONE. 3(6). e2547–e2547. 216 indexed citations

17.

Müller, Philipp, Bernhard Guggenheim, & Patrick R. Schmidlin. (2007). Efficacy of gasiform ozone and photodynamic therapy on a multispecies oral biofilm in vitro. European Journal Of Oral Sciences. 115(1). 77–80. 143 indexed citations

18.

Dreyer, M., et al.. (1989). [Single evening administration of a new antimuscarinic agent telenzepine in therapy of acute duodenal ulcer. Results of a randomized double-blind comparative study versus pirenzepine].. PubMed. 27(4). 203–6. 3 indexed citations

19.

Simon, Babette, et al.. (1988). [Ranitidine in the treatment of non-steroidal anti-inflammatory agent-induced damage of the stomach and duodenal mucosa. Results of a randomized, placebo-controlled double-blind study in patients with rheumatic diseases].. PubMed. 26(6). 310–3. 1 indexed citations

20.

Schmeer, N., et al.. (1987). Q fever vaccines for animals. Zentralblatt für Bakteriologie Mikrobiologie und Hygiene Series A Medical Microbiology Infectious Diseases Virology Parasitology. 267(1). 79–88. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact